Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.44
CBM's Cash to Debt is ranked higher than
52% of the 1244 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. CBM: 0.44 )
CBM' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: 0.44

Equity to Asset 0.52
CBM's Equity to Asset is ranked higher than
64% of the 933 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CBM: 0.52 )
CBM' s 10-Year Equity to Asset Range
Min: 0.22   Max: 0.74
Current: 0.52

0.22
0.74
F-Score: 5
Z-Score: 3.77
M-Score: -2.84
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 13.24
CBM's Operating margin (%) is ranked higher than
90% of the 1022 Companies
in the Global Biotechnology industry.

( Industry Median: -78.59 vs. CBM: 13.24 )
CBM' s 10-Year Operating margin (%) Range
Min: -2.77   Max: 18.02
Current: 13.24

-2.77
18.02
Net-margin (%) 11.00
CBM's Net-margin (%) is ranked higher than
89% of the 1022 Companies
in the Global Biotechnology industry.

( Industry Median: -78.55 vs. CBM: 11.00 )
CBM' s 10-Year Net-margin (%) Range
Min: -98.33   Max: 82.87
Current: 11

-98.33
82.87
ROE (%) 17.78
CBM's ROE (%) is ranked higher than
95% of the 1141 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. CBM: 17.78 )
CBM' s 10-Year ROE (%) Range
Min: -94.37   Max: 120.02
Current: 17.78

-94.37
120.02
ROA (%) 8.37
CBM's ROA (%) is ranked higher than
93% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: -27.84 vs. CBM: 8.37 )
CBM' s 10-Year ROA (%) Range
Min: -37.93   Max: 42.71
Current: 8.37

-37.93
42.71
ROC (Joel Greenblatt) (%) 18.40
CBM's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 1220 Companies
in the Global Biotechnology industry.

( Industry Median: -415.02 vs. CBM: 18.40 )
CBM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3.31   Max: 31.84
Current: 18.4

-3.31
31.84
Revenue Growth (3Y)(%) 10.20
CBM's Revenue Growth (3Y)(%) is ranked higher than
86% of the 727 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. CBM: 10.20 )
CBM' s 10-Year Revenue Growth (3Y)(%) Range
Min: -18   Max: 10.2
Current: 10.2

-18
10.2
EBITDA Growth (3Y)(%) 17.70
CBM's EBITDA Growth (3Y)(%) is ranked higher than
90% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. CBM: 17.70 )
CBM' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -27   Max: 32.8
Current: 17.7

-27
32.8
EPS Growth (3Y)(%) 45.20
CBM's EPS Growth (3Y)(%) is ranked higher than
96% of the 732 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. CBM: 45.20 )
CBM' s 10-Year EPS Growth (3Y)(%) Range
Min: -21.5   Max: 79.7
Current: 45.2

-21.5
79.7
» CBM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

CBM Guru Trades in Q4 2013

Chuck Royce 1,526,854 sh (+7.23%)
Steven Cohen Sold Out
Jim Simons 633,600 sh (-32.29%)
Paul Tudor Jones 19,403 sh (-57.91%)
» More
Q1 2014

CBM Guru Trades in Q1 2014

Paul Tudor Jones 18,500 sh (-4.65%)
Jim Simons 470,525 sh (-25.74%)
Chuck Royce 951,854 sh (-37.66%)
» More
Q2 2014

CBM Guru Trades in Q2 2014

Paul Tudor Jones Sold Out
Chuck Royce 801,354 sh (-15.81%)
Jim Simons 328,200 sh (-30.25%)
» More
Q3 2014

CBM Guru Trades in Q3 2014

Chuck Royce 921,629 sh (+15.01%)
Jim Simons 261,500 sh (-20.32%)
» More
» Details

Insider Trades

Latest Guru Trades with CBM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2013-03-31 Sold Out 0.09%$11.27 - $12.79 $ 21.7983%0
Joel Greenblatt 2012-12-31 New Buy0.09%$9.34 - $13.96 $ 21.7992%142352
Joel Greenblatt 2012-09-30 Sold Out 0.02%$9.01 - $13.01 $ 21.7997%0
Joel Greenblatt 2012-06-30 New Buy0.02%$5.96 - $9.16 $ 21.79208%30208
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 17.70
CBM's P/E(ttm) is ranked higher than
97% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBM: 17.70 )
CBM' s 10-Year P/E(ttm) Range
Min: 1.05   Max: 63.2
Current: 17.7

1.05
63.2
P/B 2.91
CBM's P/B is ranked higher than
85% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 6.37 vs. CBM: 2.91 )
CBM' s 10-Year P/B Range
Min: 0.61   Max: 5.22
Current: 2.91

0.61
5.22
P/S 1.96
CBM's P/S is ranked higher than
96% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 29.14 vs. CBM: 1.96 )
CBM' s 10-Year P/S Range
Min: 0.18   Max: 10.71
Current: 1.96

0.18
10.71
PFCF 16.63
CBM's PFCF is ranked higher than
98% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBM: 16.63 )
CBM' s 10-Year PFCF Range
Min: 4.81   Max: 245.33
Current: 16.63

4.81
245.33
EV-to-EBIT 15.38
CBM's EV-to-EBIT is ranked higher than
96% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBM: 15.38 )
CBM' s 10-Year EV-to-EBIT Range
Min: -2271   Max: 388.4
Current: 15.38

-2271
388.4
PEG 1.60
CBM's PEG is ranked higher than
99% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBM: 1.60 )
CBM' s 10-Year PEG Range
Min: 0.52   Max: 42.7
Current: 1.6

0.52
42.7
Shiller P/E 26.29
CBM's Shiller P/E is ranked higher than
98% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBM: 26.29 )
CBM' s 10-Year Shiller P/E Range
Min: 5.64   Max: 141.6
Current: 26.29

5.64
141.6
Current Ratio 2.18
CBM's Current Ratio is ranked higher than
61% of the 1237 Companies
in the Global Biotechnology industry.

( Industry Median: 4.71 vs. CBM: 2.18 )
CBM' s 10-Year Current Ratio Range
Min: 0.9   Max: 5.19
Current: 2.18

0.9
5.19
Quick Ratio 1.04
CBM's Quick Ratio is ranked higher than
54% of the 1237 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. CBM: 1.04 )
CBM' s 10-Year Quick Ratio Range
Min: 0.5   Max: 4.55
Current: 1.04

0.5
4.55

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 3.79
CBM's Price/Tangible Book is ranked higher than
85% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 9.60 vs. CBM: 3.79 )
CBM' s 10-Year Price/Tangible Book Range
Min: 1.63   Max: 14.41
Current: 3.79

1.63
14.41
Price/DCF (Projected) 1.97
CBM's Price/DCF (Projected) is ranked higher than
97% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBM: 1.97 )
CBM' s 10-Year Price/DCF (Projected) Range
Min: 0.83   Max: 12.66
Current: 1.97

0.83
12.66
Price/Median PS Value 1.56
CBM's Price/Median PS Value is ranked higher than
78% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 2.24 vs. CBM: 1.56 )
CBM' s 10-Year Price/Median PS Value Range
Min: 0.21   Max: 7.42
Current: 1.56

0.21
7.42
Price/Peter Lynch Fair Value 1.60
CBM's Price/Peter Lynch Fair Value is ranked higher than
99% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBM: 1.60 )
CBM' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.56   Max: 8.25
Current: 1.6

0.56
8.25
Price/Graham Number 1.70
CBM's Price/Graham Number is ranked higher than
97% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBM: 1.70 )
CBM' s 10-Year Price/Graham Number Range
Min: 0.43   Max: 4.95
Current: 1.7

0.43
4.95
Earnings Yield (Greenblatt) 6.50
CBM's Earnings Yield (Greenblatt) is ranked higher than
96% of the 1217 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. CBM: 6.50 )
CBM' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 222.1
Current: 6.5

0.3
222.1
Forward Rate of Return (Yacktman) 13.10
CBM's Forward Rate of Return (Yacktman) is ranked higher than
73% of the 164 Companies
in the Global Biotechnology industry.

( Industry Median: 16.91 vs. CBM: 13.10 )
CBM' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -42.4   Max: 21
Current: 13.1

-42.4
21

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:XBX.Germany,
Cambrex Corp was incorporated as a Delaware corporation in 1981 and began business in December 1981. It is a life sciences company that provides products and services that accelerate and improve the development and commercialization of new and generic therapeutics. The Company primarily supplies its products and services worldwide to innovator and generic pharmaceutical companies. The Company has three operating segments, which are manufacturing facilities that have been aggregated as one reportable segment. The Company participates in markets that serve the healthcare industry. Customers include generic drug companies and companies that discover and commercialize new small molecule human therapeutics using organic chemistry. The Company uses its technical expertise in a wide range of chemical processes to meet the needs of its customers for high quality products and services for specialized applications. The Company's business is primarily comprised of the custom development and manufacture of pharmaceutical ingredients derived from organic chemistry. Products and services are supplied globally to innovator and generic drug companies. Products include APIs, pharmaceutical intermediates and, to a lesser extent, other fine chemicals. The Company's products and services are sold to a diverse group of several hundred customers, with one customer, Gilead Sciences, Inc. The manufacturing of pharmaceutical products is subject to extensive regulation by governmental authorities, including the FDA, the European Medicines Agency and comparable regulatory authorities in other countries.
» More Articles for CBM

Headlines

Articles On GuruFocus.com
Cambrex Corp. Reports Operating Results (10-Q) Aug 04 2010 
Cambrex Corp. Reports Operating Results (10-Q) May 05 2010 
Does Cambrex Corporation Have Earnings Persistence? Apr 28 2010 
Cambrex Corp. Reports Operating Results (10-Q) Nov 04 2009 

More From Other Websites
Cambrex To Present At Oppenheimer 25th Annual Healthcare Conference Dec 04 2014
Cambrex To Present At Oppenheimer 25th Annual Healthcare Conference Dec 04 2014
Can the Rally in Cambrex (CBM) Shares Continue? Nov 07 2014
CAMBREX CORP Financials Nov 06 2014
10-Q for Cambrex Corp. Nov 01 2014
Cambrex posts 3Q profit Oct 30 2014
Cambrex posts 3Q profit Oct 30 2014
Cambrex Corp Earnings Call scheduled for 8:30 am ET today Oct 30 2014
CAMBREX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Oct 30 2014
Q3 2014 Cambrex Corp Earnings Release - Before Market Open Oct 30 2014
Cambrex Reports Third Quarter 2014 Financial Results Oct 30 2014
Cambrex to Announce Third Quarter 2014 Financial Results on October 30, 2014 Oct 28 2014
Cambrex to Announce Third Quarter 2014 Financial Results on October 30, 2014 Oct 28 2014
Halozyme's PEGPH20 Receives FDA Orphan Drug Designation Oct 07 2014
Alexion Pharmaceuticals (ALXN) in Focus: Stock Rises 6.0% Oct 06 2014
Weakness Seen in Vital Therapies (VTL): Stock Falls 6.3% Oct 06 2014
CorMedix Files IND Application for Neutrolin in the US Sep 30 2014
Ambit Biosciences (AMBI) Soars: Stock Adds 87.1% Sep 30 2014
Alimera/pSivida's Iluvien Receives FDA Approval for DME Sep 29 2014
Repros Therapeutics (RPRX) Worth Watching: Stock Up 17% Sep 29 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK